<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168232">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01989299</url>
  </required_header>
  <id_info>
    <org_study_id>VIP-HF</org_study_id>
    <nct_id>NCT01989299</nct_id>
  </id_info>
  <brief_title>Value of ICD Implantation in Patients With Heart Failure and Preserved Ejection Fraction</brief_title>
  <acronym>VIP-HF</acronym>
  <official_title>Value of ICD Implantation in Patients With Heart Failure and Preserved Ejection Fraction (VIP-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.C. Van Gelder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Interuniversity Cardiology Institute of the Netherlands (ICIN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trial Coordination Center UMC Groningen (TCC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Groningen</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure with preserved ejection fraction (HFPEF) is a large medical problem, for which
      no drug or device has a recommendation in current HF guidelines. Sudden cardiac death is the
      most common cause of death in HFPEF patients. Use of an Implantable Cardioverter
      Defibrillator (ICD) may be useful in some patients with HFPEF.

      The purpose of this study is to investigate the incidence of appropriate ICD shocks
      (efficacy) and inappropriate ICD shock (safety) in patients with HFPEF at high-risk for
      arrhythmic mortality.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of appropriate ICD shocks (efficacy) and inappropriate ICD shock (safety)</measure>
    <time_frame>3 years after ICD implantation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To study the incidence of appropriate ICD shocks (efficacy) and inappropriate ICD shock (safety) in patients with HFPEF at high-risk for arrhythmic mortality.
ICD implantation and treatment are associated with a number of complications. The safety of ICD treatment in patients with HEFPEF is not known. This study aims to investigate this issue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of ventricular tachyarrhythmias in this HFPEF population by implanting an implantable loop recorder (ILR).</measure>
    <time_frame>3 years after ILR implantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients with HFPEF but not eligible for the VIP-HF study because they do not meet the required arrhythmia criteria or refuse ICD implantation will be implanted with an ILR to evaluate the occurrence of ventricular tachyarrhythmias in this HFPEF population.
ILR implantation is associated with a low risk of complications.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction (HFPEF)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD implantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical criteria:

          1. Age &gt;18 years

          2. Written informed consent

          3. HF with moderate to severe symptoms NYHA II or III

          4. Hospitalization or emergency room visit for HF or symptom relief with diuretics
             within 12 months

          5. Sinus rhythm or AF with adequate rate control (exercise test: maximum heart rate &lt;160
             bpm)

        Echocardiographic criteria:

          1. LVEF &gt;40%

          2. Left atrial size (volume ≥34 mL/m2  or LA parasternal diameter ≥45), or left
             ventricular hypertrophy (septal thickness or posterior wall thickness ≥11 mm)

        Biomarker criteria:

          1. BNP &gt;100ng/L or NT-pro-BNP&gt;400ng/L if sinus rhythm

          2. BNP &gt;300ng/L or NT-pro-BNP&gt;1200ng/L if atrial fibrillation

        Arrhythmic criteria (2 of 5 necessary):

          1. &gt;3 non-sustained VTs on 24 hr Holter

          2. Heart rate turbulence (slope ≤2.5 ms/RR-interval and onset ≥0%)

          3. Heart rate deceleration capacity (≤4.5 ms)

          4. Short-term variability of repolarization quantified as STVQT  &gt; 8 ms

          5. Positive TWA score of 65 μV

        Exclusion Criteria:

          1. Patients unwilling or unable to sign informed consent

          2. Indication for ICD therapy as secondary prevention (e.g. sudden cardiac death
             survivors)

          3. Indication for ICD therapy as primary prevention according to latest guidelines (e.g.
             familial hypertrophic cardiomyopathy)

          4. Life expectancy of less than one year

          5. Significant coronary artery disease or myocardial infarction &lt; 3 months

          6. Complex congenital heart disease

          7. Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michiel Rienstra, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle C van Gelder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk J van Veldhuisen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander H Maass, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michiel Rienstra, MD, PhD</last_name>
    <phone>+31-50-361-1327</phone>
    <email>m.rienstra@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>November 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Groningen</investigator_affiliation>
    <investigator_full_name>I.C. Van Gelder</investigator_full_name>
    <investigator_title>dr.</investigator_title>
  </responsible_party>
  <keyword>Heart failure with preserved ejection fraction (HFPEF)</keyword>
  <keyword>ICD</keyword>
  <keyword>Sudden cardiac death</keyword>
  <keyword>Safety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
